HC Wainwright Issues Optimistic Outlook for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Research analysts at HC Wainwright increased their Q2 2026 earnings estimates for Eton Pharmaceuticals in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.28 per share for the quarter, up from their prior estimate of $0.27. HC Wainwright currently has a “Buy” rating and a $37.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.37 EPS, FY2026 earnings at $1.18 EPS, FY2028 earnings at $2.58 EPS and FY2029 earnings at $3.45 EPS.

A number of other research firms have also issued reports on ETON. Craig Hallum lifted their target price on Eton Pharmaceuticals from $29.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen lowered shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Zacks Research raised shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $31.00.

Eton Pharmaceuticals Stock Performance

Shares of ETON stock opened at $17.53 on Thursday. The firm has a 50 day moving average of $16.23 and a two-hundred day moving average of $17.24. The stock has a market capitalization of $470.15 million, a PE ratio of -70.12 and a beta of 1.19. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19. Eton Pharmaceuticals has a 52 week low of $11.09 and a 52 week high of $23.00.

Institutional Trading of Eton Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ETON. State of Alaska Department of Revenue purchased a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at about $30,000. Ameritas Investment Partners Inc. purchased a new stake in Eton Pharmaceuticals in the second quarter valued at approximately $37,000. Quarry LP acquired a new stake in shares of Eton Pharmaceuticals in the third quarter valued at approximately $37,000. Legal & General Group Plc purchased a new position in shares of Eton Pharmaceuticals during the second quarter worth approximately $41,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Eton Pharmaceuticals during the fourth quarter worth approximately $44,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

More Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised near‑ and long‑term EPS forecasts (Q2, Q3, Q4 2026; FY2026, FY2027, FY2028, FY2029 and beyond) and reiterated a “Buy” rating with a $37 price target — this lifts growth expectations and likely drove buying interest. Article Title
• Positive Sentiment: Craig Hallum raised its price target for ETON from $29 to $30 and maintained a “Buy” rating, adding further analyst support. Article Title
• Neutral Sentiment: Eton scheduled Q4 and full‑year 2025 earnings for March 19, 2026 with a management webcast — an important near‑term catalyst that can add volatility but will clarify fundamentals. Article Title
• Neutral Sentiment: Reported short‑interest data in the latest release was effectively zero/invalid (0 shares / NaN), so short activity is not a meaningful driver at the moment.
• Negative Sentiment: HC Wainwright trimmed its Q1 2026 EPS estimate to $0.20 from $0.23 — a near‑term downgrade that could temper sentiment if Q1 guidance or results underperform. Article Title

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.